AU2020293094A1 - Methods and compositions for altering senescence associated secretory phenotype - Google Patents

Methods and compositions for altering senescence associated secretory phenotype Download PDF

Info

Publication number
AU2020293094A1
AU2020293094A1 AU2020293094A AU2020293094A AU2020293094A1 AU 2020293094 A1 AU2020293094 A1 AU 2020293094A1 AU 2020293094 A AU2020293094 A AU 2020293094A AU 2020293094 A AU2020293094 A AU 2020293094A AU 2020293094 A1 AU2020293094 A1 AU 2020293094A1
Authority
AU
Australia
Prior art keywords
akg
composition
subject
vitamin
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020293094A
Other languages
English (en)
Inventor
Brian Kennedy
Gordon LITHGOW
Azar SHAHMIRZADI
Christopher Wiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Publication of AU2020293094A1 publication Critical patent/AU2020293094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2020293094A 2019-06-10 2020-06-10 Methods and compositions for altering senescence associated secretory phenotype Abandoned AU2020293094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859623P 2019-06-10 2019-06-10
US62/859,623 2019-06-10
PCT/US2020/036974 WO2020252005A1 (en) 2019-06-10 2020-06-10 Methods and compositions for altering senescence associated secretory phenotype

Publications (1)

Publication Number Publication Date
AU2020293094A1 true AU2020293094A1 (en) 2022-01-06

Family

ID=73781254

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020293094A Abandoned AU2020293094A1 (en) 2019-06-10 2020-06-10 Methods and compositions for altering senescence associated secretory phenotype

Country Status (7)

Country Link
US (1) US20220241229A1 (https=)
EP (1) EP3980000A4 (https=)
JP (1) JP2022536653A (https=)
CN (1) CN114126599A (https=)
AU (1) AU2020293094A1 (https=)
CA (1) CA3142781A1 (https=)
WO (1) WO2020252005A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102833111B1 (ko) 2018-09-25 2025-07-10 폰세 드 리온 헬스 데지그네이티드 액티비티 컴퍼니 칼슘 알파-케토글루타레이트의 제조 방법
DE102021111719A1 (de) * 2021-05-05 2022-11-10 Henkel Ag & Co. Kgaa Erhalt der Haarstruktur gegenüber Umwelteinflüssen umfassend ein Phenol und multivalente Ionen
US20250376678A1 (en) * 2022-04-01 2025-12-11 Japanese Foundation For Cancer Research Therapeutic agent for cancer, testing assistance method, and screening method for therapeutic agent
EP4561696A1 (en) * 2022-06-30 2025-06-04 Mechanobiologics, Inc. Reversal of cellular senescence by treatment with low frequency ultrasound
CN115813784A (zh) * 2022-11-28 2023-03-21 麦吉丽生物科技有限公司 α-酮戊二酸、含有α-酮戊二酸的米发酵液在制备皮肤炎症抑制剂中的用途
WO2024123738A1 (en) * 2022-12-06 2024-06-13 Ponce De Leon Health Designated Activity Company Compositions and methods for treating diseases responsive to akg-vitamin b coadministration

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198465A (en) * 1991-06-19 1993-03-30 Dioguardi Francesco S Compositions based on amino acids for preventing and treating precursor deficiencies in the synthesis of collagen
CA2447357A1 (en) * 2001-05-22 2002-11-28 Gene Logic, Inc. Molecular toxicology modeling
DK1824470T3 (da) * 2004-12-17 2014-08-18 Cash Alan Brian Fremgangsmåde til forlængelse af levetiden og forsinke starttidspunktet for alders-relateret sygdom
WO2007053943A1 (en) * 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
PL379512A1 (pl) * 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
MX2009013937A (es) * 2007-07-02 2010-04-30 Entress Ab Nuevo uso de compuestos quimicos farmacologicamente activos conocidos.
DE102009016119A1 (de) * 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
JP2014511890A (ja) * 2011-04-18 2014-05-19 ネステク ソシエテ アノニム α−ＨＩＣＡ及びα−ケトグルタル酸を含有する栄養組成物
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
KR20160111529A (ko) * 2014-02-12 2016-09-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 노화 및 연령 관련 질환 및 증상의 치료를 위한 조성물 및 방법
CN106963749A (zh) * 2017-03-23 2017-07-21 华南农业大学 α‑酮戊二酸（盐）在抗疲劳和提高肌肉运动力量方面的应用
SG10202107237SA (en) * 2017-04-25 2021-08-30 Buck Inst Res Aging Formulations for extending lifespan and healthspan
CN108774203A (zh) * 2018-06-25 2018-11-09 北京未蓝时代科技有限公司 一种延缓哺乳动物细胞和机体衰老的化合物及其应用
WO2020086733A1 (en) * 2018-10-24 2020-04-30 Ponce De Leon Health Designated Activity Company Nicotinamide riboside compositions for healthspan extension

Also Published As

Publication number Publication date
WO2020252005A1 (en) 2020-12-17
CN114126599A (zh) 2022-03-01
EP3980000A4 (en) 2023-06-21
CA3142781A1 (en) 2020-12-17
US20220241229A1 (en) 2022-08-04
EP3980000A1 (en) 2022-04-13
JP2022536653A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
US12220424B2 (en) Compositions comprising nicotinamide riboside and a urolithin
US20220241229A1 (en) Methods and Compositions for Altering Senescence Associated Secretory Phenotype
US11219590B2 (en) Anti-aging agent and anti-aging method
JP7745338B2 (ja) 寿命および健康寿命を延ばすための製剤
JP2009502958A (ja) ストレスの治療または管理の方法
JP2022504771A (ja) 健康寿命延長を目的とするニコチンアミドリボシド組成物
JP7633238B2 (ja) ニコチンアミドアデニンジヌクレオチド（ｎａｄ）濃度上昇剤
EP3897617A1 (en) Novel polymethoxyflavone compounds for skeletal muscle modulation, methods and uses thereof
WO2021205975A1 (ja) 細胞老化抑制用組成物及び細胞老化を抑制する方法
US11576875B2 (en) Composition comprising ethyl vanillin as effective ingredient for exhibiting effect of muscle strengthening, muscle enhancement, muscle differentiation, muscle regeneration, or sarcopenia suppression
JP7271016B2 (ja) 骨損失疾患の予防、改善または治療のためのｃｈｐ（シクロ－ヒスプロ）および副甲状腺ホルモンを含む組成物の用途
HK40071633A (en) Methods and compositions for altering senescence associated secretory phenotype
JPWO2008136173A1 (ja) スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
JP7829916B2 (ja) Ｇｒｅｍ２発現抑制剤
JP7478895B1 (ja) 痒みの予防又は改善剤
JP2003511097A (ja) 栄養補助剤
WO2024123738A1 (en) Compositions and methods for treating diseases responsive to akg-vitamin b coadministration
WO2024117172A1 (ja) 痒みの予防又は改善剤
HK40089161A (zh) 烟醯胺腺嘌呤二核苷酸(nad)浓度上升剂
JP2024079052A (ja) 痒みの予防又は改善剤
JP2018203678A (ja) 血糖上昇抑制用組成物

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application